Page 1

Omnicell NEWS RELEASE Omnicell Announces Financial Results for Third Quarter 2021 11/2/2021 GAAP and non - GAAP revenues of $ 296 million GAAP net income per diluted share of $ 0.61 Non - GAAP net income per diluted share of $ 1.08 MOUNTAIN VIEW , Calif .-- ( BUSINESS WIRE ) -- Omnicell , Inc. ( NASDAQ : OMCL ) ( " Omnicell , " " we , " " our , " " us , " " management , " or the " Company " ) , a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies , today announced results for its third quarter ended September 30 , 2021 . GAAP Results Total GAAP revenues for the third quarter of 2021 were $ 296.4 million , up $ 82.7 million , or 38.7 % , from the third quarter of 2020. The increase in GAAP revenues reflects momentum in our commercial business and strong customer implementations as well as recovery from the impact of COVID - 19 relative to the third quarter of 2020 . Total GAAP revenues for the nine months ended September 30 , 2021 were $ 821.0 million , up $ 178.0 million , or 27.7 % , from the nine months ended September 30 , 2020 . GAAP net income for the third quarter of 2021 was $ 29.3 million , or $ 0.61 per diluted share . This compares to GAAP net income of $ 8.8 million , or $ 0.20 per diluted share , for the third quarter of 2020 . GAAP net income for the nine months ended September 30 , 2021 was $ 63.9 million , or $ 1.35 per diluted share . This compares to GAAP net income of $ 15.8 million , or $ 0.36 per diluted share , for the nine months ended September 30 , 2020 . Non - GAAP Results 1